Veracyte, Inc. (VCYT) stock
VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$24.23+0.22 (+0.92%)
Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –
Veracyte price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Veracyte's price to sales ratio was 3.6× on Nov 11, 2026, against 7.6× a year earlier. Over the last 5 years it ranged from 3.6× to 15.7×, with a median of 5.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.6× | −3.1 |
| 2025 | Dec 31, 2025 | 6.7× | −0.5 |
| 2024 | Dec 31, 2024 | 7.2× | +1.4 |
| 2023 | Dec 29, 2023 | 5.9× | −0.2 |
| 2022 | Dec 30, 2022 | 6.0× | −9.7 |
| 2021 | Dec 31, 2021 | 15.7× | −9.4 |
| 2020 | Dec 31, 2020 | 25.1× | +13.4 |
| 2019 | Dec 31, 2019 | 11.7× | +5.8 |
| 2018 | Dec 31, 2018 | 5.9× | +2.8 |
| 2017 | Dec 29, 2017 | 3.1× | −0.4 |
| 2016 | Dec 30, 2016 | 3.6× | −0.6 |
| 2015 | Dec 31, 2015 | 4.2× | −2.4 |
| 2014 | Dec 31, 2014 | 6.6× | +5.9 |
| 2013 | Dec 31, 2013 | 0.7× | – |
See a number that looks wrong?